Status: Not yet recruiting
Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA prime and gp120 (A,B,C,A/E) protein HIV-1 vaccines boost (PDPHV) with either Alhydrogel or GLA-SE in healthy, HIV-uninfected adults. Volunteers will receive either the PDPHV or the placebo (normal saline) by intramuscular injections. Some volunteers will receive Alhydrogel and others will receive GLA-SE as part of the protein boost.
Participants needed: 126
Trial details
Phase: Phase 2Age: 18-55Biological sex: AllType: InterventionalSponsor: Worcester HIV VaccineUpdated: Jun 30, 2026Locations: 2
Eligibility criteria
Age of 18 to 55 years [+26]
Blood products received within 120 days before first vaccination. [+30]